A Study to Compare the Efficacy and Safety of Tacrolimus Capsules in Patient With Myasthenia Gravis
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
A Randomized, Double-blinded, Placebo-controlled, and Multi-centered Clinical Trial Evaluating the Efficacy and Safety of Tacrolimus Capsule in Myasthenia Gravis That Was Insufficiently Treated by Glucocorticoid Therapy
Study Start Date
Actual Primary Completion Date
Actual Study Completion Date
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 70 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
diagnosed as myasthenia gravis (MG) by clinical diagnosis
QMG scores ≥7 at the time of enrollment
basic treatment drugs are mainly glucocorticoids, and the efficacy of glucocorticoid therapy was not sufficient
receiving blood purification therapy or immunoglobulin therapy within 8 weeks before the study
QMG swallowing function score ≥ 2 points or QMG vital capacity = 3
abnormal hepatic functions
uncontrolled diabetes patients
immuno-inhibitors are forbidden due to malignancy, history of malignancy or history of HIV infection
patients who are allergic to Tacrolimus or macrolide antibiotics